Dear Sir, In Type I (insulin-dependent) diabetes mellitus, solid evidence has arisen from several long-term studies in large numbers of patients that strict glycaemic control decreases urinary albumin excretion and postpones or may even prevent the development of diabetic nephropathy [1] [2] [3] . There are no comparable data, however, on the long-term effect of improved glycemic control on albuminuria in Type 2 (non-insulin-dependent) diabetes. In two short-term studies recently published in Diabetologia [4, 5] , albuminuria was decreased by 3 months of diet or by 6 months of treatment with diet or oral hypoglycaemic agents in newlydiagnosed Type 2 diabetic patients. The prevalence of microalbuminuria, however, was low (28 and 7 %, respectively) and albuminuria in microalbuminuric patients only slightly increased (maximum albuminuria at the start of the studies < 70 rag/24 h).
Therefore, we decided to re-evaluate the data of a recent longitudinal study of our group [6] on the effect of 2 years insulin treatment on blood pressure and urinary albumin excretion in 41 Type 2 diabetic patients with secondary failure of oral hypoglycaemic therapy (17 females, 24 males, age, 62 + 1 [mean + SEMI years, known duration of diabetes, 11 + 1 years). Urinary tract infection was excluded in all patients. Patients were regularly seen at 4-10week intervals in our out-patient clinic.
Haemoglobin Alc fell from 9.6 + 0.3% (normal, <6.5%) to 7.0+ 0.3% (p <0.001). Hypertension (blood pressure > 160/ 95 mm Hg and/or antihypertensive treatment) was noted in 46 % of the patients; antihypertensive therapy did not change in the course of the study. Urinary albumin excretion fell from 86 + 28 to 51 + 16 mg/24 h (p < 0.05), the prevalence of albuminuria of more than 30 rag/24 h fell from 45 to 25 % (p < 0.05). Patients with persistently elevated albuminuria (group 1) differed from patients with normal or normalized albuminuria after 2 years of insulin (group 2) in more advanced renal damage (Table 1 ). In the course of the study, patients in group ] had a higher prevalence of calculated mean arterial blood pressure greater than 103 mmHg (75 vs 24%, p <0.01) and of haemoglobin Alc over 7.3 % (63 vs 45 %, p < 0.05) than patients in group 2, needed higher dosages of insulin (41 + 5 vs 32 + 3 I U/day, p < 0.05) and had higher triglyceride levels ( Table 1) .
As in patients with Type i diabetes [1, 2] , albuminuria may decrease in Type 2 diabetes if glycaemic control is improved. However, the beneficial effect of improved glycaemic control on albuminuria may be offset by hypertension or its sequelae [7] , if blood pressure is not adequately controlled. This may already be the case with blood pressure levels within the upper normal range according to World Health Organisation criteria. In Type i diabetes, the development of microalbuminuria precedes that of hypertension which in turn, as part of a vicious circle, precipitates the progression of nephropathy [3] . In Type 2 diabetes, however, hypertension preexists in about half of the patients and acts as promoter for the development of microalbuminuria [7] . Therefore, strict control of blood pressure in early Type 2 diabetes is particularly vital for the prevention of eventual renal disease. Moreover, it remains to be investigated the extent to which genetic factors associated with insulin resistance and/or lipid abnormalities may contribute to the disease mechanisms of nephropathy in Type 2 diabetes. Is glucokinase the beta-cell glucoreceptor?
Dear Sir, Having read the two recently published letters from Matschinsky [1] and Randle [2] I cannot resist making a comment. The authors of these letters each claim that they were the first to propose that glucokinase acts as a glucoreceptor in the process of glucose-induced insulin secretion. I am not sure that a decision on this issue is crucial, and consider that the progress of knowledge, rather than consideration on priority, is the scientific relevant matter. Incidentally, even in terms of priority, it could be argued that the first published report on the phosphorylation of D-glucose by islet homogenates [3] stems from Indianapolis rather than St Louis or Bristol. In this first report, the experimental data indicated the participation of a high-Km phosphorylating enzyme and were indeed compatible with the presence of glucokinase [4] . More importantly, however, I believe that the claim made by Matschinsky and Randle that glucokinase is the glucoreceptor represents a misleading concept, as has been indicated on several occasions [5, 6] . It ignores a number of regulatory steps in v-glucose metabolism proximal and distal to the site of glucose phosphorylation. Even on the latter process, it neglects the fact that the rate of D-glucose phosphorylation in intact beta-cells is not dictated solely by the concentration of the hexose and intrinsic properties of glucokinase but also by a number of other factors including ATP availability, interference of Corresponding author: Professor W.J.Malaisse, Laboratory of Experimental Medicine, Brussels Free University, 808 Route de Lennik, B-1070 Brussels, Belgium a glucokinase regulatory protein and binding of glucokinase to mitochondrial porin [7] .
The relevance of glucokinase activity to the process of glucose-induced insulin release cannot be ignored. It is equally unwise to ignore other essential regulatory mechanisms participating in the beta-cell glucose-sensing device, whoever first documented the presence of the high-Km enzyme in islet homogenates.
Yours sincerely, W. J. Malaisse
